Peel Hunt restated their under review rating on shares of Silence Therapeutics (LON:SLN) in a report issued on Monday.

Silence Therapeutics stock opened at GBX 49.40 ($0.65) on Monday. The company has a market capitalization of $35.11 million and a price-to-earnings ratio of -7.26. Silence Therapeutics has a 1 year low of GBX 46.10 ($0.60) and a 1 year high of GBX 202 ($2.64).

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Read More: Trading Ex-Dividend

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.